Update Artikelilmiah: 46930

PITRA GUNA ALAMSYAH

NIM

Judul Artikel

Abstrak (Bhs. Indonesia)

Latar Belakang : Hepatitis B kronis merupakan ancaman bagi masyarakat di dunia. Di
Indonesia, Riset Kesehatan Dasar (Riskesdas) 2017 menyebutkan bahwa pasien hepatitis B
kronis mencapai 10%. Tujuan : Penelitian ini bertujuan untuk menganalisis perbedaan efek
samping tenofovir dan entecavir terhadap kadar ureum dan kreatinin pada pasien hepatitis
B kronis di RSUD Margono Soekarjo. Metode : Penelitian ini termasuk observasional
analitik dengan mengumpulkan sebanyak 70 pasien hepatitis B kronis yang mendapatkan
terapi tenofovir atau entecavir. Data dikumpulkan dari rekam medis RSUD Margono
Soekarjo mulai dari Januari sampai Oktober 2024. Hasil : rata-rata usia pasien hepatitis B
kronis di RSUD Margono Soekarjo adalah 37,97 tahun. Pasien didominasi oleh laki-laki
sebanyak 39 pasien (55,7%). Hasil uji fisher exact menunjukkan adanya perbedaan efek
samping tenofovir dan entecavir terhadap ureum dengan nilai p 0,025. Hasil uji chi-square
menunjukkan terdapat perbedaan efek samping tenofovir dan entecavir terhadap kadar
kreatinin dengan p-value sebesar 0,040. Tenofovir cenderung menyebabkan peningkatan
kadar ureum dan kreatinin. Kesimpulan : Terdapat perbedaan efek samping tenofovir dan
entecavir terhadap kadar ureum dan kreatinin pada pasien hepatitis B kronis di RSUD
Margono Soekarjo setelah 6 bulan pengobatan. Klinisi disarankan untuk lebih berhati-hati
dalam pengobatan tenofovir dan diperlukan pemantauan secara rutin

Abtrak (Bhs. Inggris)

Background: Chronic Hepatitis B is a threat to people in the world. In Indonesia, Riset
Kesehatan Dasar (Riskesdas) 2017 stated that chronic hepatitis B patients reached 10%.
Objective : This study aims to analyze the difference in the side effects of tenofovir and
entecavir on urea and creatinine levels in chronic hepatitis B patients at Margono Soekarjo
Hospital. Methods: This study included observational analysis by collecting as many as 70
chronic hepatitis B patients who received tenofovir or entecavir therapy. Data was collected
from the medical records of Margono Soekarjo Hospital from January to October 2024.
Results: The average age of chronic hepatitis B patients at Margono Soekarjo Hospital was
37.97 years. Patients were dominated by men as many as 39 patients (55.7%). The results of
the Fisher Exact test showed that there was a difference in the side effects of tenofovir and
entecavir on urea with a p value of 0.025. The results of the chi-square test showed that there
was a difference in the side effects of tenofovir and entecavir on creatinine levels with a pvalue of 0.040. Tenofovir tends to cause increased levels of urea and creatinine. Conclusion:
There are differences in the side effects of tenofovir and entecavir on urea and creatinine
levels in chronic hepatitis B patients at Margono Soekarjo Hospital after 6 months of
treatment. Clinicians are advised to be more careful in the treatment of tenofovir and routine
monitoring is required

Kata kunci

Pembimbing 1

Pembimbing 2

Pembimbing 3

Tahun

Jumlah Halaman